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Machado-Joseph disease (MJD) is a fatal, dominant neurodegenerative disorder. MJD results from polyglu-
tamine repeat expansion in the MJD-1 gene, conferring a toxic gain of function to the ataxin-3 protein. In
this study, we aimed at overexpressing ataxin-3 in the rat brain using lentiviral vectors (LV), to generate
an in vivo MJD genetic model and, to study the disorder in defined brain regions: substantia nigra, an
area affected in MJD, cortex and striatum, regions not previously reported to be affected in MJD. LV encoding
mutant or wild-type human ataxin-3 was injected in the brain of adult rats and the animals were tested for
behavioral deficits and neuropathological abnormalities. Striatal pathology was confirmed in transgenic
mice and human tissue. In substantia nigra, unilateral overexpression of mutant ataxin-3 led to: apomor-
phine-induced turning behavior; formation of ubiquitinated ataxin-3 aggregates; a-synuclein immunoreactiv-
ity; and loss of dopaminergic markers (TH and VMAT2). No neuropathological changes were observed upon
wild-type ataxin-3 overexpression. Mutant ataxin-3 expression in striatum and cortex, resulted in accumu-
lation of misfolded ataxin-3, and within striatum, loss of neuronal markers. Striatal pathology was confirmed
by observation in MJD transgenic mice of ataxin-3 aggregates and substantial reduction of DARPP-32 immu-
noreactivity and, in human striata, by ataxin-3 inclusions, immunoreactive for ubiquitin and a-synuclein. This
study demonstrates the use of LV encoding mutant ataxin-3 to produce a model of MJD and brings evidence
of striatal pathology, suggesting that this region may contribute to dystonia and chorea observed in some
MJD patients and may represent a target for therapies.
INTRODUCTION
Machado-Joseph disease (MJD) or spinocerebellar ataxia type
3 (SCA3) is one of nine dominant neurodegenerative diseases
resulting from polyglutamine repeat expansions. It was orig-
inally described in people of Portuguese descent, particularly
from the Azores islands, where MJD is most prevalent
(1:140 in the small island of Flores). It was subsequently
identified in several other countries and is now considered
to be the most common dominantly inherited hereditary
ataxia (1).
MJD is caused by an unstable expansion of a CAG tract in
the coding region of the gene, MJD1 on chromosome 14q32.1
(2). MJD1 encodes ataxin-3, a polyubiquitin-binding protein
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whose physiological function has been linked to ubiquitin-
mediated proteolysis (3–7). The mutation results in a long
polyglutamine chain at the C-terminus of ataxin-3 (8); there
are between 10 and 51 glutamine residues in the normal popu-
lation and between 55 and 87 in MJD patients (9–11). There is
a negative correlation between the age of onset and the
number of CAG repeats, as is the case for other polyglutamine
disorders (12).
The clinical hallmark of MJD is progressive ataxia, a dys-
function of motor coordination that can affect gaze, speech,
gait and balance (13). Levodopa-responsive parkinsonism
symptoms, among other clinical features, were also reported
(14). In MJD patients, ataxin-3 is present in Marinesco
bodies which are found in substantia nigra (15–17). The neu-
ropathology of the disease involves multiple systems such as
non-cortical cerebellar systems (particularly the dentate
nucleus and pontine neurons), cranial nerve motor nuclei
and substantia nigra (1,8). Recent studies suggest that other
brain areas might be also affected in MJD. Positron emission
tomography revealed low levels of fluorodopa uptake,
dopamine transporter binding and regional cerebral glucose
metabolism in the putamen of MJD patients (18–20). Some
patients exhibit dystonia and more rarely chorea and these
symptoms are not completely explained by cerebellar neuro-
pathology, and could have contribution of striatal pathology
(21). Dementia and delirium have also been reported
suggesting that neuropathological changes might occur in
the cortex (22).
Investigations of the neuropathology of the disease and
evaluation of therapeutic approaches require animal models
that closely mimic the human pathology. The development
and study of various transgenic mouse models (23–26) have
significantly contributed to our understanding of MJD. The
localized overexpression of mutant protein using viral
vectors has been a successful alternative for modeling pathol-
ogies of the central nervous system (CNS) (27–30). This strat-
egy generates robust in vivo genetic models leading to
neuronal degeneration in defined regions of the brain. There-
fore, the aim of this work was to develop a lentiviral-based
genetic model of MJD in the rat and to evaluate the pathology
in different brain areas. In particular, we examined the sub-
stantia nigra, where overt neuropathological changes have
been described in patients, and the striatum and cortex,
which have been indirectly implicated in the pathology of
the disease.
RESULTS
Strategy used to generate an in vivo model
of Machado-Joseph disease in adult rats
The cDNA encoding human ataxin-3 with either 27 (normal;
atx3-27Q) or 72 glutamines (mutant; atx3-72Q) and contain-
ing a Myc Tag at the 50 end was inserted into the
SIN-W-PGK lentiviral backbone (Fig. 1A) such that the trans-
gene is under control of the phosphoglycerate kinase 1 (PGK)
promoter, a housekeeping promoter which allows stable long-
term expression (31). We validated these lentiviral vectors
(LV) in 293T cells (Fig. 1B–D). Five days post-infection,
both wild-type and mutant proteins were detected using
immunocytochemistry with a myc antibody (Fig. 1C–D); no
immunoreactivity (IR) was detected in non-infected cells
(Fig. 1B). These results were confirmed by western blot with
antibodies recognizing ataxin-3 (1H9), the expanded polyglu-
tamine repeats (1C2) and the Myc epitope. In all cases, wild-
type and mutant ataxin-3 proteins were detected at the pre-
dicted molecular weights and in similar amounts (Fig. 1E–
G). The 1H9 antibody, which also recognizes the endogenous
human ataxin-3 in 293T cells (Fig. 1E) revealed substantial
overexpression of the transgenic forms (27Q and 72Q) of
ataxin-3. Densitometric analysis showed that the amounts of
transgenic (27Q and 72Q) ataxin-3 were six times higher
than those of endogenous ataxin-3 (1H9 antibody). As
expected, a more robust IR signal was detected with the 1C2
antibody for mutant ataxin-3-expressing cells than for cells
expressing wild-type ataxin-3 (Fig. 1F).
In vivo, upon injection of the vectors in the rat brain human
wild-type and mutant ataxin-3 were also detected by western
blot on tissue punches (Supplementary Material, Fig. S1).
The level of transgenic wild-type ataxin-3 was four times
higher than the endogenous rat ataxin-3 (Supplementary
Material, Fig. S1A) indicating that LV allows robust overex-
pression of ataxin-3 in vivo.
Induction of a Machado-Joseph disease neuropathology
in different regions of the rat brain
We chose the substantia nigra as the reference area for the
establishment of the SCA3 model because this region is
affected in MJD patients, causing Parkinson’s disease-like
symptoms (Fig. 2A) (14). In addition, we injected vectors
into the striatum and cortex, regions which might also be
involved in the disease (Fig. 2A).
Accumulation of ubiquitinated and a-synuclein-positive
aggregates following mutant ataxin-3 expression in the
substantia nigra
Wild-type and mutant ataxin-3 were detected in the substantia
nigra 2 months after lentiviral injection, using the 1H9 anti-
body (Fig. 2B–D). Intense staining revealed production of a
substantial amount of both ataxin-3 species. The wild-type
ataxin-3 signal was diffuse, covering all subcellular structures
(Fig. 2B and C), whereas mutant ataxin-3 (72Q) detection
resulted in punctate and mainly nuclear staining (Fig. 2D
and E). This pattern suggests formation of nuclear ataxin-3
inclusions, characteristic of the disease (32).
We then used confocal microscopy to investigate whether
the mutant ataxin-3 inclusions co-localize with ubiquitin
and a-synuclein, two proteins involved in Parkinson’s
disease. As expected, no ubiquitin-IR or a-synuclein-IR
was detected in the regions injected with vectors encoding
wild-type ataxin-3 (27Q) (Fig. 2F and I). In contrast,
within the regions expressing mutant ataxin-3, 1H9-positive
aggregates were immunoreactive for ubiquitin (Fig. 2G and
H). Moreover, a considerable number of ataxin-3 aggregates
(42+ 8%) were also immunoreactive for a-synuclein
(Fig. 2J).
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Expression of mutant ataxin-3 causes depletion of neurons
immunoreactive for tyrosine hydroxylase and vesicular
monoamine transporter 2
We tested whether overexpression of mutant ataxin-3 was
associated with neuronal dysfunction by immunohistochem-
ical analysis with two markers of dopaminergic neurons, the
tyrosine hydroxylase (TH) and the vesicular monoamine trans-
porter 2 (VMAT2). Loss of TH- and VMAT2-IR was observed
in ataxin-3-72Q-injected animals (Fig. 3A and D) and high
magnification shows a high depletion of TH-positive cells
around the injection site (Fig. 3A). Double staining for TH
and ataxin-3 further confirmed the depletion of TH in expres-
sing neurons (Supplementary Material, Fig. S2B). In contrast,
TH-IR co-localized with 1H9-IR in wild-type ataxin-3 expres-
sing neurons (Supplementary Material, Fig. S2A). Quantitat-
ive analysis revealed a reduction in the number of TH-IR
neurons to 61.4+ 8.5% when compared with the non-injected
hemispheres, and no reduction of TH-IR in wild-type
ataxin-3-injected hemispheres (Fig. 3B). A reduction of TH
immunoreactivity was also observed in the striatum of
animals injected with LV encoding mutant ataxin-3 suggesting
dysfunction of the TH nigro-striatal projecting fibers (Fig. 3C).
Neuronal dysfunction was further demonstrated in sections
stained with a VMAT2 antibody. A significant reduction in
the number of neurons immunoreactive for VMAT2 was
observed in animals injected with the LV expressing mutant
ataxin-3, but not in those injected with the wild-type protein
(Fig. 3D and Supplementary Material, Fig. S2C and D).
Behavioral deficit induced by mutant ataxin-3
expression in the substantia nigra
To evaluate whether the neuropathological changes induced
by mutant ataxin-3 overexpression induced a Parkinson-like
behavioral dysfunction, a group of animals submitted to uni-
lateral injection of the mutant ataxin-3 encoding vector into
Figure 1. (A) Schematic representation of the lentiviral constructs used in the development of the animal model of Machado-Joseph disease. cDNAs encoding
human wild-type (27 CAG repeats) or mutant ataxin-3 (72 CAG repeats) were cloned in the SIN-W transfer vector. (B–D) Infection of 293T cells with wild-type
human ataxin-3 (ATX3 WT /27Q) (C) or mutant human ataxin-3 (ATX3 MUT/72Q) (D) encoding vectors containing a human Myc epitope tag at the 50 end
[anti-Myc tag (OP10) antibody (1:200)]. (E–G) The western blot analysis of 293T cells infected with lentiviral vectors encoding ATX3 WT or ATX3 MUT at 1
week post-infection. The membranes were probed with the antibodies anti-ataxin-3 (1H9) (E), 1C2 (F) and anti-Myc tag (G).
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Figure 2. (A) Rat brain regions targeted with the human ataxin-3-encoding
lentiviral vectors. Human ataxin-3 overexpression in the adult rat brain at 2
months; (B) intranigral injection of wild-type or (D) mutant ataxin-3 in
adult rats; (C) anti-ataxin-3 staining (1H9) showing the expression of the wild-
type protein in the cytoplasm and (E) the translocation of the mutant ataxin-3
to the nucleus. (G and H at high magnification) Overexpression of mutant
ataxin-3 in substantia nigra neurons promotes formation of ubiquitinated
ataxin-3 aggregates. (F) In contrast, no evidences of aggregation were
observed when wild-type ataxin-3 was overexpressed. (I and J) Counterstain-
ing with the Hoechst dye demonstrates that overexpression of mutant ataxin-3
in substantia nigra induces the formation of a-synuclein-positive aggregates in
the nucleus (J), whereas overexpression of wild-type ataxin-3 does not
promote the formation of a-synuclein positive nuclear aggregates (I).
Figure 3. Neuropathology. (A) Depletion of tyrosine hydroxylase
(TH)-positive neurons in the substantia nigra caused by overexpression of
mutant ataxin-3, suggesting neuronal dysfunction; whereas overexpression
of wild-type ataxin-3 has no deleterious effect at 2 months (i.e. no significant
difference between injected and non-injected (NI) hemispheres). (B) Quanti-
tative analysis of the number of TH-positive neurons in adult rat brains
injected in the susbstantia nigra with human ataxin-3 (P , 0,001 when
compared with all groups). (C) Striatal TH down-regulation in animals
injected in the substantia nigra with mutant ataxin-3, suggesting degeneration
of the nigro-striatal pathway. The intranigral injection of wild-type ataxin-3
does not induce TH downregulation in the striatum. (D) Reduction of
the number of vesicular monoamine transporter type 2 (VMAT2)-
immunoreactive neurons in the substantia nigra caused by overexpression
of mutant ataxin-3, suggesting neuronal dysfunction; whereas overexpression
of wild-type ataxin-3 has no deleterious effect at 2 months (no significant
difference between injected and non-injected (NI) hemispheres). (E) Beha-
vioral analysis: apomorphine-induced turning in adult rats unilaterally
lesioned with mutant ataxin-3 in the substantia nigra. Results are expressed
as the net difference between the total number of turns after and before
lesion. Ipsilateral turns were counted as positive turns, whereas contralateral
turns were counted as negative turns. Rotational behavior statistical signifi-
cance was evaluated using the Friedman test, a non-parametric test for
paired samples (P ¼ 0.018).
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the substantia nigra were tested for rotational asymmetry.
Animals injected with the mutant ataxin-3-virus displayed
more ipsilateral turning in response to the dopamine agonist
apomorphine than before injection (Fig. 3E). This motor
deficit was still detected 2 months post-injection demonstrat-
ing stability of the neuronal dysfunction.
Injection of mutant ataxin-3 in the cortex
Neuropathological examination of MJD brains indicates that
the substantia nigra, pontine nuclei, cerebellar dentate
nucleus, cranial nerve nuclei, spinal anterior horns and
Clarke’s columns are the major regions of degeneration (1).
However, there is growing clinical data and neuroradiological
evidence of striatal and cerebral cortex dysfunction in some
MJD patients (18,20,33,34). The western blot analysis indi-
cated that the ataxin-3 is expressed not only in the substantia
nigra, but also in the cortex and striatum (Fig. 4A). LV
encoding wild-type and mutant ataxin-3 were injected in the
cortex to assess the potential involvement of this structure
in MJD pathology. After 3 months, both wild-type and
mutant ataxin-3 were detected over a large region. A diffuse
pattern of wild-type ataxin-3 immunoreactivity was observed
(Fig. 4B and D), whereas numerous ubiquitin-positive nuclear
inclusions were detected with the mutant ataxin-3 (Fig. 4C, E
and G). No significant modification of the neuronal marker
NeuN was detected by immunostaining (Fig. 4I), except in a
region immediately surrounding the needle tract. These data
suggest that the presence of ataxin-3 nuclear inclusions in the
cortex is not associated with major neuropathological
changes, even 3 months post-injection of the vectors.
Striatal neuropathology due to mutant ataxin-3
overexpression
To investigate the involvement of the striatum in MJD pathol-
ogy, we injected LV encoding wild-type and mutant ataxin-3
into this brain region. At 2 weeks (Supplementary Material,
Fig. S3) and 2 months post-injection (Fig. 5, 6 and Sup-
plementary Material, Fig. S4), aggregation of mutant
ataxin-3, accompanied by ubiquitination (Fig. 5B, D, F and
Supplementary Material, Fig. S3A and E), was detected.
Additionally, at 2 months there was condensation of the cell
nucleus (Fig. 5H), loss of NeuN-IR (Fig. 5J) and
DARPP-32-IR (Supplementary Material, Fig. S4B), conden-
sation of the internal capsule of the striatum (Fig. 5L) and
fluorojade B-positive cells (Fig. 5N) within the region trans-
duced with mutant ataxin-3, whereas the hemisphere overex-
pressing wild-type ataxin-3 was unaffected (Fig. 5G, I, K, M
and Supplementary Material, Fig. S4A and C). Importantly,
the severity of the pathology was dose- and time-dependent
(Supplementary Material, Figs S5 and S3); indeed, animals
injected with 500 ng p24 and 1000 ng p24 of the vectors
encoding mutant ataxin-3 had DARPP-32-depleted volumes
of 1.12+ 0.06 and 1.51+ 0.08 mm3, respectively, 2 months
post-injection (Supplementary Material, Fig. S5E–I), and no
NeuN or DARPP-32 loss of immunoreactivity at 2 weeks
(Supplementary Material, Fig. S3C and D).
Regarding the subcellular localization of ataxin-3, wild-type
protein displayed 1H9-IR throughout cell bodies (Fig. 6A)
without ubiquitin-IR (Fig. 6A), as observed using confocal
microscopy. Wild-type ataxin-3 immunoreactivity co-localized
with DARPP-32 and NeuN stainings (Supplementary Material,
Fig. S4A and C). High magnification revealed that wild-
type ataxin-3 accumulated close to the nuclear envelope
(Fig. 6C). In contrast, mutant ataxin-3 inclusions (Fig. 6D)
are localized in dense intranuclear aggregates which were
Figure 4. (A) Western blot showing the endogenous expression of ataxin-3 in
the substantia nigra, striatum and cortex of the adult rat brain. For each brain
region, 10, 20 or 30 mg of protein were loaded, respectively. (B and C)
Anti-ataxin-3 staining (1H9) showing the efficient transduction of adult rat
cortical neurons with human ataxin-3 expressing lentiviral vectors. (D)
Expression of wild-type protein occurs both in the cytoplasm and nucleus,
whereas mutant ataxin-3 is translocated to the nucleus (E) promoting the for-
mation of ubiquitin-positive nuclear inclusions, at 3 months (G). No overt
change in NeuN staining was observed after wild-type (H) or mutant (I)
ataxin-3 expression in the rat cortex, excepting the needle tract area.
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ubiquitin-IR (Fig. 6B). In addition, at the center of the injected
region, where transgene expression levels are highest, a loss
of ataxin-3-IR (1H9), NeuN-IR or DARPP-32-IR immunor-
eactivity was observed, presumably due to cell degeneration
(Supplementary Material, Fig. S4B and D). Western blot
from striatal tissue punches revealed enrichment of wild-type
ataxin-3 in the supernatant fraction (Supplementary Material,
Fig. S1A and B), while mutant ataxin-3 was mainly detected
in the insoluble fraction. In this fraction, high molecular
weight species of mutant ataxin-3 immunoreactive for ubiqui-
tin were visible (Supplementary Material, Fig. S1C and D).
Very faint bands possibly corresponding to cleavage frag-
ments were also detected. Additional studies are, however,
warranted to further investigate the processing and appearance
of cleavage fragments.
These results, suggest that the striatum is directly involved
in Machado-Joseph pathology, improve our understanding of
the pathogenesis of the disorder and may help in the develop-
ment of therapy.
Striatal pathology in MJD transgenic mice
and patient tissue
To further confirm the involvement of the striatum in the path-
ology, MJD transgenic mice (25) and post-mortem striatal sec-
tions of MJD patient’s brains were analyzed by
immunohistochemistry. Ubiquitinated ataxin-3 aggregates
were detected throughout striata of Q71C homozygous trans-
genic mice (Fig. 7B, C, E, F and Supplementary Material,
Fig. S6B), whereas no aggregates were detected in wild-type
mice (Fig. 7A, D and Supplementary Material, Fig. S6A).
DARPP-32 staining revealed a substantial downregulation of
DARPP-32 (Fig. 7H and Supplementary Material, Figs S6D
and S7), suggesting a striatal dysfunction at 10–13 weeks.
Similar analysis was performed with striatal tissue from
three human patients (61+ 6 years, 71+ 3 CAG). Despite
technical difficulties associated with the long fixation
times – preventing DARPP-32 immunostaining – ubiquitinated
ataxin-3 inclusions were detected in the striata of the three
MJD patients (Fig. 7L, M, O and Supplementary Material,
Fig. S8). Moreover, immunoreactivity for a-synuclein
co-localizing with ataxin-3-IR was identified in intranuclear
and perinuclear inclusions found in human tissue (Fig. 7Q,
R and Supplementary Material, Fig. S8B, C, D and E).
Conversely, inclusions were absent from control tissue
(Fig. 7K, N and P), thus demonstrating neuropathology in
this region in patients.
Figure 5. (A and B) Striatal injection of wild-type and mutant human ataxin-3
in the adult rat brain. Anti-ataxin-3 staining (1H9) showing expression of the
wild-type protein in the cytoplasm (C) and translocation of the mutant ataxin-3
to the nucleus (D) inducing the formation of ubiquitin-positive aggregates at 2
months (F). (H) Pycnotic nuclei are visible on cresyl violet stained sections
suggesting possible cell injury and striatal degeneration after injection of
vectors encoding mutant ataxin-3 in adult rats, at 2 months. (J) A considerable
loss of NeuN-immunoreactive neurons was observed in the region expressing
mutant ataxin-3, whereas wild-type ataxin-3 (I) has no toxic effect. (L)
Coalescence of the internal capsule of the striatum was observed after
mutant ataxin-3 expression at 2 months on a bright-field photomicrograph,
suggesting degeneration. (K) In contrast, no signs of coalescence were
observed when wild-type ataxin-3 was expressed. (N) Striatal degeneration
in mutant ataxin-3-injected rats observed at 2 months post-injection on
Fluorojade B stained sections in contrast with wild-type ataxin-3-injected
rats (M).
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DISCUSSION
In this study, we used LV to develop an in vivo model of
MJD. We showed that LV allow robust expression of human
ataxin-3 in rat brain. Lentiviral-mediated expression of
mutant but not wild-type ataxin-3 induced behavioral and
neuropathological abnormalities associated with MJD, sup-
porting our strategy to develop an animal model of MJD.
In the first part of the study, we investigated pathological
changes at the substantia nigra, an area affected in MJD.
There are various observations implicating this area in
MJD: (i) levodopa-responsive parkinsonism has been
reported in patients (14); (ii) neuropathology has been
described in substantia nigra of affected individuals (1,8);
(iii) transgenic mice expressing mutant ataxin-3 (Q71)
develop a pathological phenotype with decreased TH-IR
neurons in the substantia nigra (25); and (iv) even non-
expanded ataxin-3 is found in intranuclear aggregates
within Marinesco bodies in human and non-human primate
substantia nigra (15–17).
Transduction of substantia nigra with LV encoding either
wild-type or mutant ataxin-3 resulted in robust transgene
expression. Wild-type ataxin-3 was evenly distributed through-
out the cell, particularly around the nuclear envelope, whereas
mutant ataxin-3 accumulated into dense neuronal intranuclear
aggregates and was depleted from the cytoplasm. Even though
a nuclear localization signal (NLS) has been identified upstream
from the polyglutamine repeat region of ataxin-3 (35), the non-
expanded protein is present both in the nucleus and in the cyto-
plasm (36); indeed, ataxin-3 possesses nucleocytoplasmic shut-
tling activity (37). Moreover, recent data showing that nuclear
localization of ataxin-3 is required for the manifestation of
symptoms in MJD have emerged (26). It has been suggested
that the nuclear environment favors a conformation of wild-type
ataxin-3 that is more likely to aggregate (38,39). Although the
role of aggregates in MJD remains controversial, they are
Figure 6. Overexpression of wild-type or mutant human ataxin-3 in the adult rat striatum, subcellular distribution and interaction with different proteins. (B)
Expression of mutant human ataxin-3 induces the formation of aggregates which are ubiquitinated particularly within the central core of the intranuclear
inclusions; (A) whereas expression of wild-type ataxin-3 is cytoplasmatic and does not promote the formation of intranuclear ubiquitin-positive inclusions;
(C) cell nuclei counterstained with Hoechst dye demonstrate that expression of wild-type ataxin-3 is predominantly perinuclear and cytoplasmatic whereas
mutant ataxin-3 is nuclear (D).
Human Molecular Genetics, 2008, Vol. 17, No. 14 2077
typical of polyglutamine disorders and have been used as indi-
cators of disease progression.
In MJD patients expanded ataxin-3 accumulates in ubiquiti-
nated neuronal intranuclear inclusions (NII) within affected
brain regions (40). Polyglutamine expansion causes ataxin-3
monomeric peptides, which exist predominantly in a random
coil conformation, to aggregate into ß-rich amyloid-like fibril-
lar structures (41). Expansion of the glutamine repeat in
ataxin-3 destabilizes the native protein structure leading to
the formation of fibrillar aggregates with increased ß-structure
and the ability to bind the amyloid dye, Congo red (42). This
implies that MJD shares pathogenic mechanisms with other
amyloid-associated diseases such as Alzheimer’s and prion’s
diseases. The identity of the pathogenic species remains
unknown – whether the protein alone, the putative intermedi-
ates of the fibrillization pathway, or the soluble mature fibrils
(43,44). Nevertheless, similarities with other misfolding ami-
loidopathies suggest that small initial aggregates, such as the
recently identified protofibrillar intermediates (43–45), may
be more toxic than large aggregates (46). While, further
studies are necessary to confirm and identify the presence of
these intermediates, our results in striatal homogenates
clearly show an accumulation of mutant ataxin-3 as insoluble
and high molecular weight species.
Another feature of mutant ataxin-3 aggregates was the pre-
sence of ubiquitin, a molecule which is closely associated with
the proposed function and structure of ataxin-3. Depending on
the isoform, ataxin-3 has two to three ubiquitin-interacting
motifs (UIMs). It has been suggested that ataxin-3 removes
ubiquitin from substrates to allow proteosomal degradation
(47). Therefore, these motifs would bind ubiquitin from poly-
ubiquitinated substrates, allowing cleavage by the ataxin-3
N-terminal Josephin domain (48). The presence of ubiquitin
in ataxin-3 aggregates may also be a consequence of
ataxin-3 itself being a substrate for ubiquitination, and thus
being degraded by the ubiquitin–proteasome pathway
(49,50). We found that a-synuclein, a presynaptic protein
widely expressed in the brain and associated with Parkinson-
ism, co-localizes with ataxin-3 inclusions in rat substantia
nigra and human striatum. a-Synuclein may be recruited
into ataxin-3 aggregates due to the propensity of this protein
and its ubiquitinated form to interact with the UIMs present
in ataxin-3. Non-expanded ataxin-3 has been reported to be
present in intranuclear aggregates within Marinesco bodies
found in human and non-human primate substantia nigra
(15–17); thus ataxin-3 may promote a-synuclein proteolysis.
Proteolytic activity of wild-type ataxin-3 suppresses neurode-
generation induced by mutant ataxin-3 in a Drosophila MJD
model (51). Further studies should be conducted to evaluate
the relationship between these two proteins.
In addition to the accumulation of NII, we observed a sub-
stantial loss of TH and VMAT2 staining within the transduced
Figure 7. Ataxin-3 (1H9) immunohistochemical staining in wild-type mice
(A) and ATXN3 Q71C homozygous transgenic mice (B). (B) Ataxin-3
immunoreactive aggregates are observed in ATXN3 Q71C homozygotes. (C)
At higher magnification, nuclear inclusions adjacent to the nucleolus are
observed. (E and F with a high magnification) Ubiquitin-positive inclusions
are present in ATXN3 Q71C homozygotes and are not observed in wild-type
animals (D). (H and J with high magnification) ATXN3 Q71C homozygotes
express lower levels of DARPP-32 than wild-type mice suggesting possible
neuronal dysfunction (G and I with high magnification). (N) The striata of
MJD patients contain ubiquitin-(O) and ataxin-3-(L) positive aggregates
with distinct nuclear inclusions (M) when compared with the control brains
(N and K, respectively). (P–R) Ataxin-3 and a-synuclein immunoreactivity
in brain sections from a MJD patient. Shown are representative confocal
laser micrographs from the striata of a MJD patient showing co-localization
of a-synuclein and ataxin-3. (Q) and (R) show intranuclear (Q) and intracyto-
plasmic (R) co-localization of ataxin-3 and a-synuclein.
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area in the substantia nigra. No co-localization of TH or
VMAT with mutant ataxin-3 was observed. These data are
in line with the reduction of TH-positive cells reported in
transgenic models of MJD (24,25). Moreover, depletion of
the number of neurons immunoreactive for TH in the substan-
tia nigra was accompanied by a similar, although less pro-
nounced reduction of TH immunoreactivity in the striatum,
indicating a loss of function of dopaminergic neuron terminals
within the striatum. These animals displayed rotational beha-
vior under apomorphine, further corroborating these neuro-
pathological observations.
MJD is characterized by degeneration of brain regions in
addition to the substantia nigra (1,8). Recently, imaging tech-
niques of MJD patient brains implicated two other areas, the
cerebral cortex and the striatum. In this study, we evaluated
the neuropathological effects of mutant ataxin-3 local overex-
pression in these regions. In the cortex, the overexpression of
mutant ataxin-3 was associated with a minor loss of NeuN
expression, in contrast to the severe pathology observed at 2
months in the substantia nigra. The cortical accumulation of
ubiquitinated ataxin-3 aggregates might nevertheless lead to
neuronal dysfunction and may explain the decrease in cerebral
glucose metabolism identified by positron emission tomogra-
phy in the cerebral cortex (18,19).
The third region that we targeted with LV was the striatum.
We found a dose-dependent loss of neuronal markers, an
accumulation of NII and high molecular weight species, and
finally cell death. Such striatal pathology was unexpected,
because there were no clear evidences of neuropathology for
this region in MJD. Imaging studies in MJD patients provided
indirect evidence that the striatum could be affected
(18,19,52). Yen et al. (20) examined dopamine transporter
binding at nigrostriatal terminals of patients using single-photon
emission computed tomography. Asymptomatic MJD gene car-
riers showed low levels of dopamine uptake in putamen,
suggesting that impairment of pre-synaptic dopamine function
occurs at an early stage. Data gathered in our rat model, in trans-
genicmice and in human tissue, demonstrate for the first time the
involvement of this structure in MJD. The potential implication
of the striatum in MJD provides an explanation for symptoms
found in MJD patients (21) particularly the fairly common
dystonia, and the more rare chorea. In animal models and in
cerebral imaging and necropsies of patients, chorea and dystonia
have been consistently associated with lesions in the striatum.
Chorea seems to involve dysfunction of the indirect pathway
from the caudate and putamen to the internal globus pallidus,
whereas dystonia is generated by dysfunction of the direct
pathway (53). Our results indicate that brain delivery of
mutant ataxin-3 with LV provides a new genetic model
of MJD which may help elucidate the molecular mechanism
of mutant ataxin-3 toxicity and will facilitate the evaluation of
new therapeutic strategies.
MATERIALS AND METHODS
Lentiviral vector production
cDNAs encoding the human wild-type ataxin-3 (Atx3-27Q) or
mutant ataxin-3 (Atx3-72Q) (genbank: S75313), isoform
mjd1a, kindly provided by Pittman and co-author (40), were
cloned in the SIN-W-PGK transfer vector (27). Viral vectors
were produced in 293T cells using a four-plasmid system
described previously (54). The lentiviral particles were pro-
duced and resuspended in phosphate-buffered saline (PBS)
with 1% bovine serum albumin (BSA) and samples were
matched for particle concentration by measuring HIV-1 p24
antigen content (RETROtek, Gentaur, France). Viral stocks
were stored at 2808C until use.
Western blot analysis
293T cells were infected with LV (300 ng of p24 antigen/well)
and cultured with fresh D-MEM (Gibco, Paisley, Scotland,
UK) containing 10% fetal bovine serum (FBS; Gibco,
Paisley, Scotland, UK), 2 mM L-glutamine, 4500 mg/l
glucose, 25 mM HEPES, 100 U/ml penicillin and 100 U/ml
streptomycin (Gibco, Paisley, Scotland, UK). Cellular lysates
were harvested 7 days post-infection in lysis buffer (150 mM
NaCl, 50 mM Tris-base, pH 7,4, 5 mM EDTA, 0.5% Triton,
1% NP 40 and 0.5% protease inhibitor cocktail; Sigma).
Protein concentration was determined with the Bradford
protein assay (BioRad, Munich, Germany). Twenty micro-
gram aliquots of the protein extracts were resolved on 12%
SDS-polyacrylamide gels and transferred onto nitrocellulose
membranes (Schleicher & Schuell Bioscience, Germany).
Immunoblotting was performed using anti-ataxin-3 antibody
(1H9; 1/1000; Chemicon, Temecula, CA, USA); anti-
polyglutamine tract antibody (1C2; 1/1000; Chemicon, Teme-
cula, CA, USA); anti-Myc tag antibody clone 4A6 (Upstate,
Cell Signalling Solutions, NY, USA; 1/500), followed by incu-
bation with an alkaline phosphatase-coupled goat anti-mouse
antibody (1:5000; Sigma, St Louis, MO, USA). The presence
of antigens was observed using a BCIP/NBT alkaline phos-
phatase substrate solution (SIGMA, St Louis, MO, USA).
In vitro immunocytochemistry
293T cells were infected with LV (150 ng of p24 antigen/well)
and cultured with fresh D-MEM (Gibco, Paisley, Scotland,
UK) containing 10% FBS (Gibco, Paisley, Scotland, UK),
2 mM L-glutamine, 4500 mg/l glucose, 25 mM HEPES,
100 U/ml penicillin and 100 U/ml streptomycin (Gibco,
Paisley, Scotland, UK). Five days post-infection, the cell cul-
tures were washed with PBS and fixed with paraformaldehyde
(PAF) 4% in PBS. Immunostaining was performed using the
primary monoclonal anti-Myc tag antibody clone 4A6
(Upstate, Cell Signalling Solutions, NY, USA) diluted in
PBS/0.1% Triton X-100 containing 10% Normal Goat
Serum (NGS; 1/500; Gibco, Paisley, Scotland, UK), followed
by incubation with a biotinylated anti-mouse secondary anti-
body (1:200; Vector Laboratories). Bound antibodies were
visualized using the Vectastain ABC kit, with
3,30-diaminobenzidine tetrahydrochloride (DAB metal con-
centrate; Pierce) as substrate.
In vivo experiments
Adult male Wistar rats (Iffa Credo/Charles River, Les Oncins,
France), weighing 200 g were used. The animals were
housed in a temperature-controlled room and maintained on
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a 12 h light/dark cycle. Food and water were available ad
libitum. The experiments were carried out in accordance
with the European Community Council directive (86/609/
EEC) for the care and use of laboratory animals.
Endogenous rat ataxin-3 and human ataxin-3
detection by western blot
Brain punches of substantia nigra, cortex and striatum of adult
rats were collected and processed to evaluate endogenous
ataxin-3 levels. To analyse the in vivo expression of human
ataxin-3, brain punch biopsies of 2.0 mm in diameter were
obtained by dissection of striatal injected areas on dry ice
after slicing the brain in a rat slicer matrix with 2.0 mm
coronal slice intervals. Brain sections were snap-frozen on
dry ice and stored at 2808C. Frozen tissue was prepared for
immunoblot analysis by placing in the lysis buffer previously
described followed by probe sonication. Samples were then
frozen in liquid nitrogen three times and centrifuged for
30 min at 14 000 g to remove insoluble material, obtaining
the supernatant fraction. Protein concentration was determined
with the Bradford protein assay (BioRad, Munich, Germany).
The pellet fraction was then resuspended in 2% SDS. The blot-
ting procedure was similar to the one previously described.
The antibodies used were the following: anti-ataxin-3 antibody
(1H9; 1/1000; Chemicon, Temecula, CA, USA); anti-Myc tag
antibody clone 4A6 (1/500; Upstate, Cell Signalling Solutions,
NY, USA); anti-tubulin antibody (1:10000; Sigma, Saint
Louis, MO, USA) and anti-ubiquitin antibody (1:1000;
Dakocytomation, Zug, Switzerland). Blots were washed
followed by incubation with the respective IgG HRP-coupled
biotinylated goat secondary antibody (1:5000; Vector Labora-
tories, Burlingame, CA, USA) for 1 h at RT. The presence of
antigens was observed using Enhanced Chemilunescence
Reaction (ECLþ, Amersham Pharmacia Biotech, Les Ulis,
France).
In vivo injection of lentiviral vectors
Concentrated viral stocks were thawed on ice and resus-
pended by repeated pipetting. LV encoding human wild-type
(Atx3-27Q) or mutant ataxin-3 (Atx3-72Q) were stereotaxically
injected into the substantia nigra, cortex or striatum of anesthe-
tized animals. Animals were anesthetized by administration of
ketamine (75 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.). Particle
contents were determined by p24 antigen ELISA (RETROtek,
Gentaur, France) and the appropriate amounts were injected
into the different rat brain areas through a 34-gauge blunt-tip
needle linked to a Hamilton syringe (Hamilton, Reno, NV,
USA) by a polyethylene catheter.
Injection in the substantia nigra, cortex and striatum
LV expressing human wild-type (Atx3-27Q) (n ¼ 7) or mutant
ataxin-3 (Atx3-72Q) (n ¼ 6) were unilaterally injected into the
substantia nigra. The viral suspensions (125 000 ng of p24/ml)
were injected at 0.2 ml/min by means of an automatic injector
(Stoelting Co., Wood Dale, IL, USA). The animals received
2.4 ml of lentivirus at two sites, with the following coordi-
nates: 24.8 rostral to bregma, 2.0 lateral to midline and
–7.7 ventral from the skull surface, with the mouth bar set
at 23.3 (site 1); 25.5 rostral to bregma, 1.7 lateral to
midline, and –7.7 ventral from the skull surface, with the
mouth bar set at 23.3 (site 2). LV expressing wild-type
human ataxin-3 or mutant human ataxin-3 (n ¼ 8) were
injected in the left or right cortex. The animals received a
single 4 ml injection of 125 000 ng of p24/ml lentivirus in
each side at the following coordinates: 22.7 rostral to
bregma, +4 lateral to midline, and 4 ventral from the skull
surface, with the mouth bar set at 0 (site 1). LV expressing
wild-type human ataxin-3 or mutant human ataxin-3 (n ¼ 6)
were injected into the left and right striatum. The dose of
vector particles administered was 125 000 or 250 000 ng of
p24/ml for the dose/effect study (n ¼ 8). The animals received
a single 4 ml injection of lentivirus in each side at the follow-
ing coordinates: 0.5 rostral to bregma, +3 lateral to midline
and 5 ventral from the skull surface, with the mouth bar set
at 0 (site 1). After injection, the syringe needle was left in
place for an additional 5 min before being slowly raised.
The skin was closed using a 6–0 Prolenew suture (Ethicon,
Johnson and Johnson, Brussels, Belgium).
Immunohistochemical procedure
Two months after lentiviral injection into the substantia nigra,
2 weeks and 2 months after injection in the striatum or 3
months after injection into the cortex, the animals were
given a sodium pentobarbital overdose and were transcardially
perfused with a phosphate solution followed by fixation with
4% PAF (Fluka, Sigma, Buchs, Switzerland) and 10% picric
acid. The brains were removed and post-fixed in 4% PAF
and 10% picric acid for 24 h and cryoprotected by incubation
in 25% sucrose/0.1 M phosphate buffer for 48 h. The brains
were frozen and 25 mm coronal sections were cut using a
sliding microtome (Cryocut 1800, Leica Microsystems AG,
Glattbrugg, Switzerland) at 2208C. Slices throughout the
entire substantia nigra, cortex or striatum were collected in
anatomical series and stored in 96-well trays (TPP, Switzer-
land) as free-floating sections in PBS supplemented with
0.12 mM sodium azide. The trays were stored at 48C until
immunohistochemical processing. Sections from injected rats
were processed with the following primary antibodies: a
mouse monoclonal anti-ataxin-3 antibody (1H9; 1:500; Che-
micon, Temecula, CA, USA), recognizing the human
ataxin-3 fragment from amino acids F112-L249 an affinity-
purified rabbit polyclonal anti-TH antibody (AB152, 1:1000;
Chemicon, Temecula, CA, USA); an affinity-purified rabbit
polyclonal anti-vesicular monoamine transporter 2 (VMAT2)
antibody (AB1767; 1:1000; Chemicon, Temecula, CA,
USA); a rabbit polyclonal anti-ubiquitin antibody (Dako,
1:1000; Cambridgeshire, UK); a rabbit polyclonal
anti-DARPP-32 antibody recognizing the 32 kDa dopamine-
and cAMP-regulated phosphoprotein (AB1656; 1:5000); a
mouse monoclonal anti-neuronal nuclei (NeuN) antibody
(MAB377; 1:500; Chemicon, Temecula, CA, USA), followed
by incubation with the respective biotinylated secondary anti-
bodies (1:200; Vector Laboratories). Bound antibodies were
visualized using the Vectastain ABC kit, with 3,30-diamino-
benzidine tetrahydrochloride (DAB metal concentrate;
Pierce) as substrate. Degenerating neurons were stained with
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the anionic fluorescein derivative Fluoro-Jade B (55). The
sections were first washed in water and then mounted on
sylanized glass slides, dehydrated and stained according to
the supplier’s manual (56).
Double stainings were performed for Ataxin-3 (1H9 Ab)
and ubiquitin, for Ataxin-3 (1H9 Ab) and TH, for Ataxin-3
(1H9 Ab) and VMAT2 or Ataxin-3 (1H9 Ab) and a-synuclein
(abcam ab6162). Free-floating sections from injected rats were
processed with the described primary antibodies at RT for 1 h
in PBS/0.1% Triton X-100 containing 10% NGS (Gibco) or
5% NDS (Normal Donkey Serum, Sigma, Saint Louis, MO,
USA) (for Ataxin-3 and a-synuclein), then overnight at 48C
in blocking solution with the following antibodies: 1H9
(1:5000) and anti-ubiquitin (1:1000); 1H9 (1:5000) and
anti-TH (1:1000), 1H9 (1:5000) and anti-VMAT2 (1:1000),
1H9 (1:5000) and anti-DARPP-32 (1:2000), polyclonal
anti-ataxin-3 (1:2000), kindly provided by Dr Henry
L. Paulson, anti-NeuN (1:500) or 1H9 (1:5000) and anti-
a-synuclein (1:500) antibodies diluted in the respective block-
ing solution. Sections were washed three times and incubated
for 2 h at RT with the corresponding secondary antibodies
coupled to fluorophores (1:200; Molecular Probes, OR,
USA) diluted in the respective blocking solution. The
nuclear localization of ataxin-3 was investigated on sections
double-stained for ataxin-3 (1H9 Ab) and Hoechst. The sec-
tions were washed three times and then mounted in Fluorsave
Reagent (Calbiochem, Germany) on microscope slides.
Cresyl violet staining
Coronal 25 mm-thick striatal sections were cut using a freez-
ing microtome (Cryocut 1800, Leica Microsystems AG, Glatt-
brugg, Switzerland). Premounted sections were stained with
cresyl violet for 2 min, differentiated in acetate buffer pH
3.8–4 (2.72% sodium acetate and 1.2% acetic acid; 1:4 v/v),
dehydrated by passing twice through ethanol and toluol sol-
utions, and mounted onto microscope slides with Eukitt w
(O. Kindler GmbH & CO. Freiburg, Germany).
Transgenic mice
Mice (10–13 weeks old) were wild-type (n ¼ 4) or Q71C
homozygous transgenic mice (n ¼ 4) expressing human
mutant (Q71) ataxin-3 mjd1 under the control of the mouse
prion promoter. Q71C homozygotes were at a late stage of
the disease (25). Brains were cut using a freezing microtome
(Cryocut 1800, Leica Microsystems AG, Glattbrugg, Switzer-
land) and immunohistochemistry was performed as described
above, using anti-Ataxin-3 (1H9) (1:2000), anti-ubiquitin
(1:1000) and anti-DARPP32 (1:4000) antibodies.
Human tissue
Postmortem striatal tissue from three MJD patients with mor-
phologically and genetically confirmed MJD (61+ 6 years,
71+ 3 CAG number of mutant allele) and a 65-year-old
control with no evidence of neurologic disease were obtained
from the Neurology and Pathology Services, VA Medical
Center, Albany Medical College, Albany, New York, NY,
USA. The tissue was fresh when dissected and then placed
in cold (48C) at 10% neutral buffered formalin. Anti-ataxin-3
(1:1000) and anti-ubiquitin (1:1000) immunostainings were
performed as previously described including the citrate
buffer epitope retrieval method. Double stainings for
Ataxin-3 (1H9; 1:2000; Chemicon, Temecula, CA, USA)
and synuclein (anti-a-synuclein; No. 2628; 1:500; Cell Signal-
ing), for ubiquitin (Dako, Cambridgeshire, 1:1000; UK) and
synuclein (anti-a-b-synuclein; No. 2644; 1:500; Cell Signal-
ing) were performed as previously described.
Behavioral analysis
Apomorphine-induced rotational asymmetry was measured
three times before virus injection. Animals were injected sub-
cutaneously with 1.0 mg/kg apomorphine (Amino AG,
Neunhof, Switzerland) and placed into a test chamber (Rotos-
can, Rotometer v5.06, Omnitech Instruments, Columbus, OH,
USA) for a 3 min habituation period before a 45 min test
session. Rotations were defined as complete 3608 ipsilateral
turns; the net difference between the two directions is
reported. Animals that did not display spontaneous turning
behavior (less than 20 turns per 45 min) were selected.
Results are expressed as the net difference between the total
number of turns before and after lesion. Ipsilateral turns
were counted as positive turns, whereas contralateral turns
were counted as negative turns.
Quantification of tyrosine hydroxylase-positive neurons
We used an Olympus CKX41 light microscope with a 10
magnification lens with a hand tally clicker counter to count
TH-positive neurons in TH-stained coronal sections (200 mm
between 25 mm thickness sections).
Evaluation of the volume of DARPP-32 depleted region
The extent of ataxin-3 lesions in the striatum was analyzed by
digitizing ten DARPP-32-stained sections per animal (200 mm
between 25 mm thickness sections), selected to obtain a com-
plete rostrocaudal sampling of the striatum with a slide
scanner and by quantifying the area of the lesion with a semi-
automated image-analysis program (ImageJ software, NIH,
MD, USA). Sections throughout the entire striatum were ana-
lyzed. The area of the striatum showing a loss of DARPP-32
staining was measured for each animal with an operator-
independent macro. The volume was then estimated using
the following formula: volume ¼ d(a1þa2þa3þ. . .), where
d is the distance between serial sections (200 or 300 mm),
and a1, a2, a3 etc. are DARPP-32-depleted areas for individ-
ual serial sections (57). The average gray value of all pixels
measured in the lesioned area was recorded for each depleted
area. Results are presented as the calculated value for volume
of the DARPP-32 depleted region for each animal.
Statistical analysis
All quantifications are expressed as mean+SEM. TH and
DARPP-32 immunostaining statistical analyses were per-
formed using one-way analysis of variance (ANOVA) fol-
lowed by a Scheffe’s protected least significant difference
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post hoc test (StatView 4.0, version 3.2.6; Aladdin Systems).
Statistical significance for rotational behavior was evaluated
using the Friedman test, a non-parametric test for paired
samples. Optical densities for DARPP-32 in wild-type and
Q71C homozygous transgenic mice were analyzed using the
Student’s t-test. Significance thresholds were set at P , 0.05
for all tests.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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